Results 151 to 160 of about 620,962 (211)

Forecasting heart failure: Seasonal alignment of heart failure outcomes in New York

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 819-831, April 2025.
Abstract Background Seasonal variations have been observed in heart failure (HF) hospitalization. Numerous explanatory mechanisms have been proposed, but no prior studies have examined potential contributors directly. Our objective was to identify specific factors that could contribute to seasonal variability using a large longitudinal dataset of HF ...
Prerna Gupta   +5 more
wiley   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy   +15 more
wiley   +1 more source

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch   +8 more
wiley   +1 more source

Clinical utility and safety of finerenone in patients with heart failure: Rationale and design of FINE registry

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Information about current use of finerenone in patients with heart failure (HF) finerenone in clinical practice is scarce, and its effectiveness in clinical practice in patients is scarce. We aim to assess both the baseline clinical profile and prognostic role of finerenone in patients with HF, irrespective of ejection fraction.
Gonzalo Luis Alonso Salinas   +32 more
wiley   +1 more source

Acute myocarditis according to age: Presentation, management and early outcomes

open access: yesESC Heart Failure, EarlyView.
MIS, multisystem inflammatory syndrome; MRE, myocarditis‐related events (within 30 days included all‐cause death, cardiogenic shock, cardiac arrest, ventricular arrhythmias or complete AV block). Abstract Aims Acute myocarditis (AM) is a rare but severe disease affecting patients of all ages. Large multicentric studies comparing children and adults are
Clément Karsenty   +25 more
wiley   +1 more source

Sex differences in the association between nutritional status and in‐hospital mortality in HFpEF patients

open access: yesESC Heart Failure, EarlyView.
Abstract Aims The study aimed to assess whether the effect of nutritional risk score (NRS‐2002) on the odds of in‐hospital mortality would be modulated by sex and body mass index (BMI) in patients with heart failure with preserved ejection fraction (HFpEF).
Michał Czapla   +8 more
wiley   +1 more source

Current and novel biomarkers in cardiogenic shock

open access: yesEuropean Journal of Heart Failure, EarlyView.
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko   +5 more
wiley   +1 more source

Association of a remote monitoring programme with all‐cause mortality and hospitalizations in patients with heart failure: National‐scale, real‐world evidence from a 3‐year propensity score analysis of the TELESAT‐HF study

open access: yesEuropean Journal of Heart Failure, EarlyView.
Association of a remote monitoring programme (RMP) with all‐cause mortality and hospitalization in heart failure (HF) patients. COPD, chronic obstructive pulmonary oedema; HR, hazard ratio; ICU, intensive care unit; LTI, long‐term illness; RR, rate ratio; SoC, standard of care.
Nicolas Girerd   +12 more
wiley   +1 more source

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant‐level pooled analysis of the CANVAS and CREDENCE trials

open access: yesEuropean Journal of Heart Failure, EarlyView.
Among high‐risk patients with T2D, new oral loop diuretic intensification was frequent and portended adverse prognostic significance. Treatment with canagliflozin significantly reduced the need for loop diuretic intensification. ABSTRACT Aims The sodium–glucose cotransporter 2 inhibitor canagliflozin reduces the risk of heart failure (HF ...
Safia Chatur   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy